Take a look at some of Wednesday's midday movers:» Read More
Wall Street analysts had estimated a potential market of $3 billion for the devices made by Medtronic Inc, Boston Scientific Corp and St Jude Medical Inc. But failure of the high-stakes clinical trial set off a heated debate between doctors who believe the approach is worth saving and those who say results show it provides no clear benefit.
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Feb 18- Medtronic Inc on Tuesday reported a lower quarterly net profit after it took charges for an experimental blood pressure device that failed to prove effective in a clinical study. Medtronic shares fell 2.3 percent to $55.56 in morning trading on the New York Stock Exchange.
Feb 18- Medtronic Inc on Tuesday reported lower quarterly net earnings due to charges for the failed clinical study of a treatment being developed for high blood pressure. Excluding the charges and other one-time items, Medtronic earned 91 cents a share, in line with the analysts' average estimate, according to Thomson Reuters I/B/E/S.
Some of Monday's midday movers:
Jim Cramer usually recommends letting reason be your guide. But in this case, it’s may be ok to follow your heart.
Feb 4- Medtronic Inc's stumble in its U.S. medical device study to treat high blood pressure could create an opportunity for other device makers to pick up where their rival has left off, Boston Scientific Corp Chief Executive Mike Mahoney said on Tuesday.
Feb 4- Boston Scientific Corp on Tuesday reported higher-than-expected quarterly results, citing improving demand for its devices that manage irregular heart rhythms. Boston Scientific is also expected to benefit from the introduction of its S-ICD system.
Jude said it expected 2014 revenue in the range of $5.6 billion to $5.75 billion, and earnings of $3.94 to $3.99 per share. Jude said on Jan. 13 its fourth quarter had been better than expected and that it would report earnings of 97 cents to 99 cents per share, excluding restructuring costs and charges.
Some of the names on the move ahead of the open.
Jan 22- St. Jude Medical Inc on Wednesday reported a higher fourth-quarter profit, as it had indicated it would, and forecast growth in both earnings and revenue in 2014.. Jude on Jan. 13 said that the fourth quarter had been better than expected and that it would report earnings of 97 cents to 99 cents per share, excluding restructuring costs and charges.
Jan 21- Jan 21- Covidien Plc said it would stop making a device for treating high blood pressure due to weak demand for the product, raising more doubts about the future of the novel technology.
U.S. stock index futures signalled a higher opening after a strong Tuesday trading day.
Some of Monday's midday movers:
"Mad Money" host Jim Cramer made calls on stocks viewers asked about.
Take a look at some of Wednesday's midday movers:
With a deadline hanging over Congress, stocks could be whipped by headlines from Washington but should ultimately be able to limp through the drama.
Talking Squawk looks at our big interviews with Daryl from "The Walking Dead", Jack Welch, Jim Chanos and T. Boone Pickens. Plus, we debate the merits of megayachts versus kayaks.
For investors still uncertain about the euro zone's prospects, analysts say there is a safer way to play its nascent recovery: Buy shares of U.S. companies that do a lot of business there.
Stocks squeezed out modest gains in choppy trading Wednesday, following comments from Fed Chairman Ben Bernanke that monetary policy will remain highly accommodative even as the central bank could start to scale back its bond buying later this year.